The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

November 25, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Abuse-Deterrent Oxycodone Capsules on Hold
The U.S. Food and Drug Administration (FDA) has granted tentative approval for extended-release, abuse-deterrent oxycodone capsules (Xtampza ER) to manage pain severe enough to require around-the-clock, long-term opioid treatment for patients who find alternative treatments inadequate.1 The FDA determined that this product meets all the required safety, quality and efficacy standards for approval, but the approval is tentative due to ongoing litigation with Purdue Pharma (filed in March 2015). The product has received an automatic 30-month stay or availability hold. The FDA can provide final approval for the drug only if the litigation is resolved prior to the expiration of the 30-month period.

You Might Also Like
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
  • Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
Also By This Author
  • FDA Approves Baricitinib for RA Patients

DETERx technology manufactured the product, which addresses common methods of abuse, including chewing, crushing and/or dissolving, and then snorting, injecting or taking it orally.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Obinutuzumab for Lupus Nephritis
Obinutuzumab, a CD20-directed cytolytic antibody that is FDA-approved for treating chronic lymphocytic leukemia along with chlorambucil, is being investigated to treat lupus nephritis.2

The study, a Phase 2 clinical trial known as NOBILITY, will compare the safety and efficacy of 1,000 mg obinutuzumab in combination with corticosteroids and mycophenolate vs. corticosteroids and mycophenolate with placebo in patients with International Society of Nephrology (ISN)/Renal Pathology Society (RPS) 2003 Classification of Lupus Nephritis Class III or IV proliferative lupus nephritis. The primary outcome measure of NOBILITY is the percentage of patients who achieve complete renal response at Week 52.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Subcutaneous Belimumab Investigated for SLE
BLISS-SC is a Phase 3 multicenter, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab administered subcutaneously to patients with active autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy.3 In this study, 200 mg belimumab (Benlysta) administered weekly and subcutaneously plus standard of care were shown to have significantly greater reductions in disease activity compared with placebo plus standard of care (61% vs. 48%).

The primary efficacy end point was the Systemic Lupus Erythematosus Responder Index response rate at Week 52.4 The belimumab regimen also met the secondary end point of delaying the time to severe flare (170 days) vs. placebo and standard care (117 days). Additionally, 18% of patients were able to reduce their steroid dose by 25% or more (for those taking >7.5 mg prednisone daily) compared with 12% of patients receiving the placebo and standard care regimen, which was not statistically significant.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: belimumab, Lupus nephritis, obinutuzumab, Oxycodone, SLE, systemic lupus erythematosus (SLE)

You Might Also Like:
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
  • Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)